Ibudilast: Difference between revisions

	WikiDoc Resources for Ibudilast
Articles
Most recent articles on Ibudilast Most cited articles on Ibudilast Review articles on Ibudilast Articles on Ibudilast in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ibudilast Images of Ibudilast Photos of Ibudilast Podcasts & MP3s on Ibudilast Videos on Ibudilast
Evidence Based Medicine
Cochrane Collaboration on Ibudilast Bandolier on Ibudilast TRIP on Ibudilast
Clinical Trials
Ongoing Trials on Ibudilast at Clinical Trials.gov Trial results on Ibudilast Clinical Trials on Ibudilast at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ibudilast NICE Guidance on Ibudilast NHS PRODIGY Guidance FDA on Ibudilast CDC on Ibudilast
Books
Books on Ibudilast
News
Ibudilast in the news Be alerted to news on Ibudilast News trends on Ibudilast
Commentary
Blogs on Ibudilast
Definitions
Definitions of Ibudilast
Patient Resources / Community
Patient resources on Ibudilast Discussion groups on Ibudilast Patient Handouts on Ibudilast Directions to Hospitals Treating Ibudilast Risk calculators and risk factors for Ibudilast
Healthcare Provider Resources
Symptoms of Ibudilast Causes & Risk Factors for Ibudilast Diagnostic studies for Ibudilast Treatment of Ibudilast
Continuing Medical Education (CME)
CME Programs on Ibudilast
International
Ibudilast en Espanol Ibudilast en Francais
Business
Ibudilast in the Marketplace Patents on Ibudilast
Experimental / Informatics
List of terms related to Ibudilast

Ibudilast
	Error creating thumbnail: File missing
Identifiers
	IUPAC name 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one;
CAS Number	50847-11-5;
PubChem CID	3671;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C14H18N2O
Molar mass	230.31 g/mol

Latest revision as of 16:29, 20 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ibudilast (AV-411) is an antiinflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE-4 subtype to the greatest extent,^[1] but also showing significant inhibition of other PDE subtypes.^[2]^[3]

Ibudilast has bronchodilator, vasodilator ^[4] and neuroprotective effects,^[5]^[6] and and is mainly used in the treatment of asthma and stroke.^[7] It inhibits platelet aggregation,^[8] and may also be useful in the treatment of multiple sclerosis.^[9]

Ibudilast crosses the blood-brain barrier and suppreses glial cell activation. This activity has been shown to make ibudilast useful in the treatment of neuropathic pain and it not only enhances analgesia produced by opioid drugs, but also reduces the development of tolerance.^[10]

Template:Pharma-stub

References

↑ Huang Z, Liu S, Zhang L, Salem M, Greig GM, Chan CC, Natsumeda Y, Noguchi K. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sciences. 2006 May 1;78(23):2663-8.
↑ Suzumura A, Ito A, Yoshikawa M, Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Research. 1999 Aug 7;837(1-2):203-12.
↑ Gibson LC, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, Mackenzie FL, Nagasawa M, Stevens PA, Mackenzie SJ. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. European Journal of Pharmacology. 2006 May 24;538(1-3):39-42.
↑ Kishi Y, Ohta S, Kasuya N, Sakita S, Ashikaga T, Isobe M. Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovascular Drug Reviews. 2001 Fall;19(3):215-25.
↑ Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004 Mar;46(3):404-11.
↑ Yoshioka M, Suda N, Mori K, Ueno K, Itoh Y, Togashi H, Matsumoto M. Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia. Pharmacological Research. 2002 Apr;45(4):305-11.
↑ Wakita H, Tomimoto H, Akiguchi I, Lin JX, Ihara M, Ohtani R, Shibata M. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Research. 2003 Nov 28;992(1):53-9.
↑ Rile G, Yatomi Y, Qi R, Satoh K, Ozaki Y. Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells. Thrombosis Research. 2001 May 1;102(3):239-46.
↑ Feng J, Misu T, Fujihara K, Sakoda S, Nakatsuji Y, Fukaura H, Kikuchi S, Tashiro K, Suzumura A, Ishii N, Sugamura K, Nakashima I, Itoyama Y. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Multiple Sclerosis. 2004 Oct;10(5):494-8.
↑ Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opinion on Investigational Drugs. 2007 Jul;16(7):935-50.

Template:Phosphodiesterase inhibitors Template:WikiDoc Sources

[1] Huang Z, Liu S, Zhang L, Salem M, Greig GM, Chan CC, Natsumeda Y, Noguchi K. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sciences. 2006 May 1;78(23):2663-8.

[2] Suzumura A, Ito A, Yoshikawa M, Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Research. 1999 Aug 7;837(1-2):203-12.

[3] Gibson LC, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, Mackenzie FL, Nagasawa M, Stevens PA, Mackenzie SJ. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. European Journal of Pharmacology. 2006 May 24;538(1-3):39-42.

[4] Kishi Y, Ohta S, Kasuya N, Sakita S, Ashikaga T, Isobe M. Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovascular Drug Reviews. 2001 Fall;19(3):215-25.

[5] Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004 Mar;46(3):404-11.

[6] Yoshioka M, Suda N, Mori K, Ueno K, Itoh Y, Togashi H, Matsumoto M. Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia. Pharmacological Research. 2002 Apr;45(4):305-11.

[7] Wakita H, Tomimoto H, Akiguchi I, Lin JX, Ihara M, Ohtani R, Shibata M. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Research. 2003 Nov 28;992(1):53-9.

[8] Rile G, Yatomi Y, Qi R, Satoh K, Ozaki Y. Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells. Thrombosis Research. 2001 May 1;102(3):239-46.

[9] Feng J, Misu T, Fujihara K, Sakoda S, Nakatsuji Y, Fukaura H, Kikuchi S, Tashiro K, Suzumura A, Ishii N, Sugamura K, Nakashima I, Itoyama Y. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Multiple Sclerosis. 2004 Oct;10(5):494-8.

[10] Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opinion on Investigational Drugs. 2007 Jul;16(7):935-50.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

Revision as of 14:50, 13 April 2015 view source Rabin Bista (talk \| contribs) nocaptcha, Administrators 4,526 edits No edit summary	Latest revision as of 16:29, 20 August 2015 view source WikiBot (talk \| contribs) Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators 57,550 edits m Protected "Ibudilast": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))
(No difference)

Identifiers
Error creating thumbnail: File missing
IUPAC name 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one
CAS Number	50847-11-5
PubChem CID	3671
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₄H₁₈N₂O
Molar mass	230.31 g/mol

Ibudilast: Difference between revisions

Latest revision as of 16:29, 20 August 2015

Overview

References

Navigation menu

Search